CEO Executive AssistantContract manufacturing organizations (CMOs) are a critical part of most pharmaceutical companies’ supply networks. Whether a company relies on external manufacturers for active pharmaceutical ingredients, drug product manufacturing, or fill-finish operations, the CEO is ultimately accountable for supply continuity, product quality, and regulatory compliance across those relationships. Yet the operational complexity of CMO management makes direct CEO involvement neither practical nor efficient.
This guide outlines how pharma CEOs can build a delegation structure for external manufacturing oversight that ensures accountability, protects product quality, and preserves supply security without requiring the CEO to be involved in day-to-day vendor management.
The Strategic Stakes of External Manufacturing
Before addressing delegation, it is worth being clear about why external manufacturing oversight matters at the CEO level. CMO failures can trigger supply shortages, FDA warning letters, product recalls, and reputational damage. In some cases, dependence on a single external manufacturer for a critical supply step creates existential risk for the company’s ability to supply patients and generate revenue.
These stakes mean that while CMO management is operationally a supply chain and technical operations function, the CEO cannot treat it as entirely outside their field of view. The challenge is to maintain appropriate strategic oversight without becoming involved in the batch record reviews and vendor audit schedules that should belong to operations and quality teams.
Defining the Delegation Layers for CMO Oversight
CEO-level accountability
The CEO retains responsibility for two things in external manufacturing: approving the overall external manufacturing strategy (which capabilities to outsource, which to retain internally, and how much supply concentration risk is acceptable) and receiving timely notification of events that could affect supply continuity or regulatory standing.
These are governance responsibilities, not operational ones. The CEO should not be scheduling CMO audits or reviewing batch disposition decisions.
VP or SVP of Technical Operations or Manufacturing
The head of technical operations is the primary owner of CMO relationships from an operational standpoint. This leader is accountable for site selection, contract negotiations (with legal and finance), ongoing performance management, and escalation of supply risks. The CEO should have a strong, trusted leader in this role and should hold them accountable through structured reporting rather than informal oversight.
Quality organization
The Head of Quality or VP of Quality Assurance is accountable for CMO quality oversight, including audit programs, batch disposition, deviation management, and regulatory inspection readiness at external sites. Quality oversight of CMOs is a specialized function that requires deep technical expertise and cannot be effectively second-guessed by non-quality personnel, including the CEO.
Supply chain and procurement
Supply planning, demand forecasting, and contract terms management belong to the supply chain and procurement organizations. These functions work in coordination with technical operations but have distinct accountability for commercial terms and supply continuity planning.
What the CEO Should and Should Not Own
One of the most common mistakes pharma CEOs make in external manufacturing is attempting to manage vendor relationships directly. When CEOs attend CMO business reviews, negotiate directly with CMO executives, or express preferences about specific manufacturing sites, they undermine the authority of the technical operations team and create confusion about who is actually accountable for the relationship.
The CEO’s direct involvement in CMO relationships should be limited to:
Strategic partnerships with major CMOs where the relationship has board-level implications or where the CMO is manufacturing the company’s most critical products. In these situations, periodic CEO-to-CEO relationship management is appropriate as long as operational accountability remains with the technical operations team.
Situations involving imminent supply disruption or regulatory action. If a CMO receives an FDA warning letter affecting a product, if a critical manufacturing step fails, or if a CMO announces it is exiting the market, the CEO needs to be in the loop immediately and should be directly involved in the response strategy.
Contract decisions above a defined financial threshold. Major CMO agreements representing significant multi-year spend should require CEO approval as part of the normal authorization framework, with the technical and legal terms negotiated by the operations and legal teams.
Everything else, including site audits, process validation, batch release decisions, and routine performance reviews, should be fully delegated.
Building the Governance Structure
Effective delegation of CMO oversight requires a governance structure that gives the CEO visibility without requiring continuous involvement. The recommended structure includes:
Monthly supply and quality dashboard. The technical operations and quality teams provide a single integrated dashboard covering CMO performance, batch success rates, deviation trends, audit findings, and supply security indicators. This dashboard should flag anything approaching a threshold that warrants CEO attention, so that the CEO is reading signals rather than reviewing raw data.
Quarterly CMO portfolio review. The VP of Technical Operations presents a portfolio-level view of all external manufacturing relationships: strategic fit, performance trends, risk concentration, and planned actions. This 60-minute review gives the CEO the information needed to make portfolio-level decisions about insourcing, dual-sourcing, or changing external partners.
Defined escalation triggers. The delegation framework should specify the conditions under which the technical operations or quality teams must immediately notify the CEO. These include: supply shortages affecting patients, FDA or EMA regulatory actions at a CMO site, major CMO contract failures, and any event triggering a product recall or market withdrawal.
Annual strategy review. Once per year, the CEO should conduct a formal review of the company’s external manufacturing strategy, including an assessment of outsourcing versus insourcing decisions, supply risk concentration, and CMO partnership quality. This review informs capital allocation decisions and organizational capability planning.
Managing the People Dimension
CMO oversight requires not just organizational structure but the right leadership capabilities. Pharma CEOs should invest in ensuring that the technical operations function is led by someone with deep CMO relationship management experience, regulatory knowledge, and operational credibility.
One of the most common reasons CEOs get pulled into CMO issues is that they lack confidence in the technical operations leader’s ability to manage complex external relationships independently. The solution is not for the CEO to stay involved; it is to find the right leader and build their capability to manage these relationships autonomously.
When selecting or developing the VP of Technical Operations, pharma CEOs should look for leaders who have:
Experience managing multi-site CMO portfolios across different dosage forms and regions, a track record of managing through supply disruptions and regulatory inspections without executive intervention, strong supplier relationship management skills at both the operational and executive level, and the ability to make and defend quality and supply risk decisions with confidence.
Regulatory Considerations in CMO Delegation
Regulatory agencies hold pharmaceutical companies, not their CMOs, responsible for product quality and GMP compliance at external manufacturing sites. This means that even when manufacturing is fully outsourced, the pharma company’s quality organization must maintain active oversight of CMO sites.
CEOs should understand that quality oversight of CMOs cannot be treated as a purely operational matter to be fully delegated without governance structures. The FDA’s expectations for oversight of contract manufacturers are clearly established, and companies that treat CMO quality as an external vendor management issue rather than an internal quality accountability have faced regulatory consequences.
The practical implication for delegation is that the quality organization should have full authority and resources to conduct audits, require corrective actions, and, where necessary, recommend discontinuing a CMO relationship on quality grounds. The CEO should make clear to the quality team that they have the organizational backing to exercise this authority even when it creates operational or commercial complications.
Handling CMO Consolidation and Strategic Shifts
External manufacturing strategy is not static. CMO consolidation, technology changes (such as the shift to continuous manufacturing or biologics), and geopolitical supply chain risks create regular pressure on pharma companies to reassess their external manufacturing footprints.
These strategic reassessments are where CEO involvement is most valuable. Decisions about whether to insource a previously outsourced capability, invest in a preferred CMO through a strategic partnership or equity stake, or shift manufacturing to a different geography require CEO-level judgment about risk tolerance, capital allocation, and long-term strategic direction.
The technical operations team should be tasked with preparing strategic options analyses for these decisions, but the final choice should rest with the CEO and, where appropriate, the board.
For pharma CEOs looking to build broader supply chain delegation systems, the supply chain delegation guide provides additional context. For the regulatory dimensions of external manufacturing oversight, the regulatory affairs guide is relevant.
Practical Steps for Implementing the Framework
Pharma CEOs who want to build or improve their external manufacturing delegation framework can take the following steps:
First, audit the current state of CMO oversight. Identify where CEO involvement is occurring at an operational level and map that work back to the appropriate functional owner.
Second, assess the capability of the technical operations and quality leadership. If these leaders are not operating with full accountability and confidence, determine whether the gap is capability, authority, or organizational structure.
Third, establish the governance calendar and dashboard infrastructure. Many companies have the right people but lack the reporting cadence that keeps the CEO appropriately informed without requiring constant involvement.
Fourth, define and communicate the escalation framework. Technical operations and quality leaders should know exactly when they are expected to escalate to the CEO and what information is needed when they do.
Fifth, conduct an annual external manufacturing strategy review that informs capital and resource allocation decisions for the following year.
Conclusion
External manufacturing oversight is a domain where pharma CEOs face real accountability but should exercise delegation as the primary operating mode. By building the right leadership team, establishing clear governance structures, and defining escalation triggers that bring the CEO in at the right moments, pharma companies can manage CMO portfolios with operational excellence without consuming CEO bandwidth that belongs elsewhere. The goal is a technical operations organization that operates independently and effectively, with the CEO serving as the strategic decision-maker and governance anchor rather than the operational supervisor.
Related Reading
For further context, explore Delegation Guide for Affordable Housing Nonprofit CEOs and Delegation Guide for Automotive CEO: Brand Management.